VMT 250 mgml Oral Solution

Country: Malaysia

Language: English

Source: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Active ingredient:

TILMICOSIN PHOSPHATE

Available from:

Shennong Animal Health (Malaysia) Sdn. Bhd.

INN (International Name):

TILMICOSIN PHOSPHATE

Units in package:

1l kg

Manufactured by:

Shennong Animal Health (Malaysia) Sdn. Bhd.

Summary of Product characteristics

VMT 250 MG/ML
ORAL SOLUTION
(FOR VETERINARY USE ONLY)
COMPOSITION
Each 1000 ml contents:
Tilmicosin (as Phosphate)
……………………………....………... 250 g
Benzyl alcohol
………………………………………………..………….
10 ml
PRODUCT DESCRIPTION
This product is brownish color clear solution.
PHARMACODYNAMICS
Tilmicosin is a semi-synthetic antibiotic of the macrolide
group, and is believed to affect protein synthesis. It has
bacteriostatic action but at high concentrations it may be
bactericidal.
This antibacterial activity is predominantly against Gram-
positive microorganism with activity against certain gram-
negative ones and Mycoplasma of a bovine, porcine, ovine
and
avian
origin.
In
particular,
its
activity
has
been
demonstrated against the following microorganism:
Chickens:
Mycoplasma
gallisepticum
and
Mycoplasma
synoviae
Scientific
evidence
suggests
that
macrolides
act
synergistically with the host immune system. Macrolides
appear to enhance phagocyte killing of bacteria. Tilmicosin
has been shown to inhibit in vitro the replication of the
Porcine
Reproductive and Respiratory
Syndrome virus
in
alveolar macrophages in a dose dependent fashion.
Cross-resistance between tilmicosin and other macrolides
and lincomycin has been observed.
PHARMACOKINETICS
Whilst blood concentrations of tilmicosin are low, there is
pH-dependent
macrophage
accumulation
of
tilmicosin
in
inflamed tissue.
Poultry: As early as 6 hours after oral administration of 75
mg
tilmicosin/litre
drinking
water,
the
average
active
substance
concentrations
detected
in
lung
and
alveolar
tissue were 0.63 μg/g and 0.30 μg/g respectively. 48 hours
after
the
start
of
the
treatment,
the
tilmicosin
concentrations in lung and alveolar tissue were 2.3 μg/g and
3.29 μg/g respectively.
TARGET SPECIES
Chickens
(except
hens
producing
eggs
for
human
consumption)
INDICATIONS
Chickens: For the treatment and prevention of respiratory
disease
in
chicken
flocks,
associated
with
mycoplasma
gallisepticum and Mycoplasma synoviae.